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Non-alcoholic fatty liver disease (NAFLD) is a crucial health problem with a 
prevalence that is increasing concurrently with the obesity epidemic on a global 
scale. Steatosis, nonalcoholic steatohepatitis (NASH), hepatocellular carcinoma 
(HCC), cirrhosis, and advanced fibrosis constitute the disease spectrum covered 
by NAFLD. NASH-related cirrhosis and HCC is currently the second most common 
indication for liver transplantation. Although lifestyle modifications, especially 
weight loss, effectively reduces the liver injury in NASH, adherence in the clinical 
setting is low. Potential treatments for NASH are still under investigation in phase 
2–3 studies. Bariatric surgery can improve metabolic components and cause great 
weight loss. Therefore, bariatric surgery may reverse the pathological liver changes 
in NAFLD and NASH patients. However, complications such as liver failure after 
bariatric surgery can occur. This chapter will give an overview of the benefits and 
pitfalls of bariatric surgery in patients with NAFLD, liver transplant candidates and 
post-liver transplant patients.
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1. Introduction
Over the last decades, there has been a drastic increase in obesity prevalence. 
Health statistics reports of 2018 showed that 40% of the total adult population of 
the United States were obese (BMI (body mass index) > 30 kg/m2).
The obesity epidemic has led to a dramatic rise in the obesity-related liver 
disease non-alcoholic fatty liver disease (NAFLD). NAFLD currentlyaffects one 
quarter of the global population [1]. Steatosis or fatty liver, non-alcoholic steato-
hepatitis (NASH), fibrosis, cirrhosis, and hepatocellular carcinoma (HCC) make up 
the spectrum of conditions that NAFLD represents. The frequency of liver trans-
plantation undertaken in patients with cirrhosis and HCC due to NASH has been 
increasing worldwide [2]. NAFLD has also been found to be associated with several 
health conditions like cardiovascular diseases which affect organs outside the liver 
and consititute the major cause of deaths in patients with NAFLD.
Lifestyle modification is the cornerstone of NAFLD therapy. As a matter of 
fact, reduced intake of calories combined with increased activity can make this 
achievable. The main driver of NAFLD improvement is the amount of actual weight 
loss, while the type of diet seems to be less important. Rrespective of how one 
achieves weight loss, the highest rates of steatohepatitis resolution (90%) as well as 
improvement of fibrosis (45%) can only be induced by >10% weight loss. A weight 
loss of >5% improves steatosis in about 64% and weight loss of >7% can resolve 
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steatohepatitis in 72% [3]. Regrettably, the necessary weight loss goal of >7% to 
10% is achieved only by a minority of the patients.
Currently, a vast array of drugs are being tested for NASH, and some of them 
are already in the third phase, but until now, there is no pharmacological therapy 
for NASH [4]. In our current understanding, any pharmacological treatment that is 
indicative for NASH should be prescribed only to patients with NASH and advanced 
liver fibrosis. The recommendations above result from data which show that fibrosis 
is the strongest prognostic predictor, with a decline in survival from fibrosis stage 2 
onwards [5].
The use of bariatric surgery as a therapy for obesity is increasingly common, and 
evidence that also supports its therapeutic use for metabolic disturbances (so called 
“metabolic surgery”) is increasing [6]. In addition, bariatric surgery is a promising 
therapeutic alternative for NAFLD as risk factors such as diabetes, inflammation, 
insulin resistance, and dyslipidemia that contribute to NAFLD pathogenesis can 
be reversed by it, and it is also effective for achieving long-term weight loss in 
patients [7].
According to current reimbursement guidelines, it is only administered to obese 
patients who are 18 years or over with a BMI > 40 kg/m2 or BMI > 35 kg/m2 with 
related co-morbidities such as diabetes mellitus, uncontrolled arterial high blood 
pressure and OSAS despite triple therapy. Consequently, NASH is not one of the 
co-morbidities regarded as an indication for bariatric surgery.
In this chapter, we will first elucidate the benefit of bariatric surgery in the 
field of NAFLD. Secondly, the possible role of bariatric surgery will be discussedin 
patients who are candidates for liver transplantation. Special considerationwill also 
be given to patients who develop recurrent or de novo NASH after liver transplan-
tation. Finally, we outline the possible pitfalls with the risk of liver failure after 
bariatric surgery.
2. Types of bariatric surgery
A variety of procedures for bariatric surgery have been developed over the last 
decades. The 2 most frequently performed types of bariatric surgery are Roux-en-Y 
gastric bypass (RYGB) and Sleeve gastrectomy (SG). There has been a progressive 
decline in the use of the adjustable gastric banding procedure after sleeve gastrec-
tomy was developed. Biliopancreatic diversion with duodenal switch (BPD–DS) 
is the procedure of choice for severe morbidly obese patients. Very low mortality 
and morbidity rates are associated with almost all bariatric operations performed 
laparoscopically [8]. In the USA and countries around the world, the currently most 
performed bariatric procedure is sleeve gastrectomy. The increase in popularity of 
the SG could be due to its relative technical simplicity, as there are no concerns for 
late complications such as internal herniation, ulcerations on anastomosis and no 
malabsorption of iron, calcium and vitamins. Malabsorptive surgery as jejunoileal 
bypass, biliopancreatic diversion (BDP), biliopancreatic diversion with duodenal 
switch (BDP-DS), and distal gastric bypass (D-GBP) can lead to large weight loss, 
yet can cause severe long-term complications.
Figure 1 shows the different types of surgery. The RYGB procedure consists 
of two components. First, a small gastric pouch of ∼30 cm3 in volume is con-
structed, secondly the small intestine is divided ∼30–50 cm distal to the ligament 
of Treitz. The distal end of the small intestine that has been divided also known 
as the Roux limb is connected to the gastric pouch that was newly fabricated. The 
Roux limb ranges from 75–150 cm in length. SG is formed from a tubular gastric 
pouch (sleeve) that remains after ∼80% of the lateral part of the stomach has 
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been removed. The BPD–DS is a procedure where first a vertical gastrectomy is 
performed, similar to the SG. Next, a large portion (∼50%) of the small intestine 
is bypassed, which creates malabsorption. The duodenum is divided immediately 
after the pylorus. At 250 cm proximal to the ileocecal valve, a portion of the distal 
ileum is divided and anastomosed to the duodenum in a Roux-en-Y configuration 
after bringing it up. Another anastomosis of the ileoileostomy is performed at 
100 cm proximal to the ileocaecal valve to complete the operation [9].
3. Benefits of bariatric surgery in NAFLD patients
Already in 2008, Mathurin et al. published data showing animprovement of ste-
atosis, ballooning and NAS score 5 years after bariatric surgery in NAFLD patients. 
However they reporteda worsening of fibrosis in 19.8% of patients. This initial find-
ing made the use of bariatric surgery questionable in the area of NASH. However, 
the worsening of fibrosis at 5 years was slight, 95% of the patients had a fibrosis 
score less than 1 and a lot of patients had no biopsy-proven NASH [10]. The same 
Figure 1. 
Bariatric surgery procedures.(A) sleeve gastrectomy, (B) roux-en-Y gastric bypass, (C) biliopancreatic 
diversion with duodenal switch (reproduced with permission from www.uzgent.be).
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group reported recently data of a biopsy-proven cohort of NASH patients with liver 
samples 1 and 5 years after bariatric surgery [11, 12]. In this long-term prospective 
trial, NASH resolution was induced by bariatric surgery without fibrosis worsen-
ing in 84% of the patients at 5 years. Regression of fibrosis was seen in 70% of the 
patients, beginning to improve within 1 year and continued throughout 5 year 
follow-up. Also in patients with baseline fibrosis grade 3, there was an improvement 
seen in 68%.The non-responders (20%) to bariatric surgery were patients with low 
weight loss and less improvement in insulin resistance after their surgery. This large 
trial has demonstrated that there is an understandable benefit to consider bariatric 
surgery as a treatment option for patients with clinically significant NASH.
Lee et al. published in 2019 a systematic review with data of 32 cohort studies 
comprising 3093 biopsy-confirmed NAFLD patients and the effect of bariatric 
surgery [13]. The authors looked at complete resolution of the different features of 
NAFLD instead of improvement. The study results indicated that there was complete 
resolution of steatosis, inflammation, ballooning and fibrosis in 66%, 50%, 76% and 
40%, respectively. A meta-analysis in 2008 of 15 cohort studies showed similar results 
[14]. By focusing on complete NAFLD resolution, these reviews provide further 
evidence that bariatric surgery is efficacious and that NAFLD as a comorbidity should 
prompt evaluation for bariatric surgery in patients with a BMI of 35 to 40 kg/m2.
Klebanoff et al. showed that bariatric surgery led to more QALY’s for all obese 
patients and overweight patients regardless of fibrosis stage compared to lifestyle 
interventions. Their analysis also suggests that for patients in all obesity classes, 
bariatric surgery, as a therapy, is cost-effective and may even be considered cost-
effective therapy for overweight individuals with advanced fibrosis [15]. The 
majority of the patients in the reported cohorts underwent RYGB, only 5 to 10% 
underwent Sleeve gastrectomy. A few studies have examined the effect other 
bariatric surgeries have on NASH. Caiazzo et al. showed that RYGB was associated 
with significantly greater improvement in the amount of steatosis and NASH at 1 
and 5 years after surgery compared to adjustable gastric banding [16].
The use of comparative randomized trials that study the impact of bariatric 
surgery compared with current medical therapies should be the focus of future 
clinical studies. Data on new endoscopic bariatric therapies and the effect on NASH 
are also urgently needed.
4. Bariatric surgery related to liver transplantation
Candidates for transplantation with a BMI > 40 kg/m2havea significantly higher 
mortality on the waiting list compared with candidates with a BMI > 30 kg/m2. 
The reason is a faster progression of liver detioration among obese patients versus 
nonobese [17]. The most frequently used BMI cutoffs in the literature as relative and 
absolute contra-indication for livertransplantation were 40 and 45, respectively. 
This is mainly based on the fact that studies reported a higher risk of perioperative 
complications, mostly wound-related infections, in obese patients. Morbid obesity 
cannot be considered as an absolute contra-indication for liver transplant despite 
the presence of associated complications in these patients. This observation leads us 
to the need to address obesity before and after liver transplantation.
4.1 Bariatric surgery in pre-liver transplant candidates
Treating obesity before transplantation can reduce the risk of decompensation 
and reduce co-morbiditities such infections and metabolic syndrome in the post-
operative period [18, 19].
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The first issue to consider is whether bariatric surgery is safe in cirrotic patients. 
Data are mostly coming from retrospective incidental findings at the time of 
bariatric surgery with a prevalence between 0.14% to 1.5% [20, 21]. Younus et al. 
described a cohort of 26 patients with incidental finding of cirrhosis (proven with 
biopsy) at the time of bariatric surgery [20]. The type of procedure was mainly 
RYGB (55%). A higher risk of immediate complications postoperative (38.5% 
versus 16.7% in non-cirrhotic group) was seen, probably also dueto a high BMI in 
this study (median BMI of 52 kg/m2). No long-term cirrhosis-related complica-
tions or increased mortality were noted in this cohort. Jan et al. published a review 
with pooled data of nine similar studies with a total of 122 cirrhotic patients. The 
characteristics of the patients were mainly Child Pugh A patients, a few Child 
Pugh B and 7 patients with portal hypertension. The type of procedure was again 
predominantly RYGB. There was an overall complication rate of 22.5% with also 
a 6.5% liver decompensation rate and a late mortality rate of 2.45%. A lower 
complication rate in cirrhotic patientswas seen in the group who underwent SG or 
gastric banding when compared with malabsorptive bariatric procedures including 
RYGB [22].
Bariatric surgery can be done in a carefully selected patient group with cir-
rhosis, especially Child Pugh A patients without significant portal hypertension. 
It is important to recognize and diagnose cirrhosis, estimate liver function and the 
presence or absence of portal hypertension pre-operatively. This can help in decid-
ing the type of procedure and anticipatingcomplications. Most of the data currently 
available indicatethat sleeve gastrectomy can be done safely in compensated liver 
cirrhosis patients [23, 24].
The risk of 30-day mortality in decompensated cirrotic patients undergoing 
bariatric surgery was noted to be 16.7% versus 0.9% in compensated cirrhosis. So, 
bariatric surgery is absolutely contra-indicated in patients with a decompensated 
liver disease.
4.2 Bariatric surgery simultaneously with liver transplantation
For patients who are too sick before transplant, a simultaneous bariatric 
surgery and liver transplantation is another approach to manage obesity in this 
population. Small series of patients who underwent combined sleeve gastrectomy 
and liver transplantation has been published from the group of the Mayo Clinic 
[25]. Death, graft loss, operative complications were similar between the two 
groups, however post-liver transplantation metabolic outcomes were superior 
in the group who underwentthe combined SG and transplantation. Long-term 
outcomes were described recently with demonstrating efficacy and maintaining 
wieght loss and favorable metabolic profiles [26]. So far, there are only two other 
case reports of sleeve gastrectomy and liver transplantation combined that have 
been reported [27, 28].
The main disadvantage of this approach can be the impact on the nutritional 
state in the immediate post-operative period. More data and experience in is needed 
before promoting this approach.
4.3 Bariatric surgery after liver transplantation
Long-term weight gain and development of metabolic syndrome are the main 
concerns post-liver transplantation. Up to 46% of the patients will develop themet-
abolic syndrome, especially those with a BMI > 30 kg/m2 or higherpre-liver trans-
plant BMI. Recently it has been shown that NASH liver transplant recipients have a 
10 year graft survival of 61% which is significantly lower than primary sclerosing 
Advances in Hepatology
6
cholangitis, auto-immuun hepatitis and primary biliary cholangitisrecipients 
(respectively 74%, 71,7% and 71%) [29]. Probably the outcomes of NASH cirrhosis 
liver transplant recipients are not as good as previously thought and this is due to 
the development of metabolic risk factors. The bulk of weight gain appears to occur 
within the first year, with studies reporting a median weight gain of 5 to 10 kg at 
12 months after liver transplantation. Recurrent NAFLD/NASH after transplanta-
tion is very common, ranging in cohorts from respectively 10 to 100% and 4 to 28%. 
Risk factors are older age, higher BMI at the time of liver transplantation, presence 
of diabetes mellitus type 2 pre-livertransplant and dislipidemia [30–32].
The development of de novo NAFLD is also frequent after liver transplantation. 
There are reports that described 78% de novo NAFLD and 4% NASH in 2378 liver 
transplant recipients at 5 year follow-up [33]. A very important finding is the faster 
progression of fibrosis in patients with de novo NASH after liver transplantation 
[30–33].
Case reports and series of bariatric surgery in post transplant recipients showed 
no difference in mortality with the general population [34–36]. Sleeve gastrectomy 
is the most performed procedure with lack of malabsorption and no interference of 
immuunsuppressive drugs. Optimal timing of bariatric surgery post liver transplan-
tation need to be defined, because delaying too long can cause fibrosis and reduce 
patient survival.
5. Liver failure as a result of prior bariatric surgery
Decompensated cirrhosis that results from an earlier bariatric surgery, is a 
clinical condition that is far more demanding. Complications including severely 
impaired hepatic function are mostly described after jejunoileal bypass (JIB) and 
biliopancreatic diversion (BPD) procedures. They occurred in up to 10% of the 
patients. The occurrence of these and other complications resulted in abandonment 
of JIB surgery. The frequency of hepatic complications after BPD is unclear, but 
hepatocellular failure has been reported in small series and case reports. In 1992, 
the first case of chronic end-stage liver disease after BPD was reported [37]. We 
published a multicenter Belgian Survey on liver transplantation for hepatocellular 
failure after bariatric surgery. 10 patients who underwent bariatric surgery and 
developed liver failure afterward were reported in the Belgian survey: 1 after JIB 
and 9 after BPD. Patients who underwent JIB or BPD subsequently became candi-
dates for liver transplantation, even >20 years after bariatric surgery [38]. Probably, 
the real incidence of hepatic complications after BPD surgery is underreported in 
the current literature; so we are still unaware of the real incidence of Scopinaro 
procedure-induced liver failure. The pathogenesis of post-BPD steatohepatitis 
remains poorly understood. One important factor implicated in the pathogenesis 
of liver injury after JIB or BPD was intestinal bacterial overgrowth in the excluded 
small intestine segment. As we see no liver failure after equivalent intestinal resec-
tion, this may explain the role of excluded segment. Bacterial overgrowth leads to 
mucosal injury and increases gut permeability toespecially endotoxins. When these 
toxins are absorbed via the portal vein to the liver, they can induce hepatocellular 
damage. Another factor in the pathogenesis of liver failure postbypass surgery 
is protein and amino acid malnutrition, which can perpetuate or increase lipid 
accumulation in the liver.
Mahawar et al. confirmed that the lenght of the biliopancreatic limb (BPL) 
matters [39]. A long BPL (100–150 cm) results in better weight loss, intensifies 
the antidiabetic effect in RYGB compared with a shorter BPL of 50–75 cm. The 
increased risk of insufficiency of protein with successive malnutrition constitute 
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the drawback of using a long BPL with a shorter alimentary limb lenght (TALL). 
Recent data suggests that at least 350–400 cm of TALL must remain [40, 41].
Although liver transplantation and intestinal anatomy restoration have been 
regarded as the standard therapy for liver failure that results from BDP or JIB 
surgery, the use of these measures has been reported to be unsuccessful in some 
cases [42, 43]. We reported a case of refractory subacute steatohepatitis after BPD 
[43]. There may be a significant improvement when surgery is used to achieve a 
gastric bypass-like anatomy, however, its feasibility is directly related to the severity 
of liver decompensation as well as effects of nutritional correction. Correction of 
vitamine depletion, malnutrition and aggressive nutrition is warranted and might 
already significantly improve the patient’s condition. In case of incipient deteriora-
tion, early referral to a liver transplant center is necessary.
The exact magnitude of liver failure after RYGB, which is not associated with 
much malabsorption, has not yet been fully established. There are some case 
reports. Mahawar et al. found10 reports of liver failure after RYGB in the entire 
surgical literature [39]. In view of the fact that RYGB is the most common per-
formed bariatric procedure worldwide, potentially millions have been carried out, 
this means that only a minuscule proportion of patients undergoing this operation 
would suffer from liver failure.
4 out of the 10 reports were seen in cirrhotic patients, 2 had extended limb 
RYGB, 1 distal RYGB, 2 had early or late complication. Extended limb or distal 
versions of RYGB can behave like biliopancreatic diversion with higher potential for 
malabsorption. These versions of RYGB may hence be more likely to predispose to 
liver failure.
High risk groups of patients undergoing RYGB, such as patients with incidental 
finding of cirrhosis, extented limb or distal versions of RYGB, complications of 
surgery and alcohol abuse, should be follow up carefully withroutine lifelong 
monitoring of liver function tests.
6. Conclusions
Bariatric surgery provides effective treatment for obesity and metabolic com-
plications. Lifestyle modification with weight loss is currently the most important 
treatment in NAFLD patients, but this is hard to achieve in clinical practice. Recent 
reports showed that bariatric surgery could resolve NASH in 84%of the patients 
without worsening of fibrosis. These findings support the notionthat bariatric sur-
gery is an effective treatment for NASH patients. Bariatric surgery, especially sleeve 
gastrectomy, also seems to be feasible in compensated cirrhotic patients. Special 
attention should be paid to recurrent and de novo NAFLD after liver transplanta-
tion. It is worthy of note that, on a case-by-case basis and prior to liver transplanta-
tion, the feasibility of bariatric surgery as well as interventions and how they are 
timed and sequenced should be discussed in a broad multidisciplinary discussion.
Liver decompensation or failure hardly occurs in patients undergoing RYGB 
without pre-existing cirrhosis. Potentially fatal liver complications are described 
with severe malabsorptive bariatric procedures such as biliopancreatic diversion or 
distal versions of RYGB. Closely monitoring of liver function is recommended in 
this high risk group and early referral for surgical conversion is necessary.
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